Specialist HIV company ViiV Healthcare, majority owned by GSK (LON:GSK), with Shionogi as a shareholder, said on Monday that it has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to expand the approved use of its HIV treatments Tivicay (dolutegravir) and Dovato (dolutegravir/lamivudine) to younger children.
The recommendation for Tivicay includes use in term newborns from birth weighing at least 2kg, potentially making it the first second-generation integrase inhibitor available for eligible newborns in the European Union. Dovato has been recommended for a new dispersible tablet formulation for children aged at least three months and weighing between 6kg and 25kg, as well as an expanded indication for its existing tablet formulation.
If approved, Dovato could become the first single-tablet, two-drug HIV treatment option for eligible younger children in the EU.
The recommendations are supported by paediatric clinical studies and pharmacokinetic modelling, with safety and tolerability profiles consistent with those observed in older children and adults.
European Commission decisions on both applications are expected in the first quarter of 2027. A separate US application for Dovato's paediatric use is also under review, with a decision expected in the same quarter.
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m